Open AccessPB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS‐5)
Author(s) -
Hamadani M.,
Linhares Y.,
Gandhi M. D.,
Chung M.,
Adamis H.,
Ungar D.,
CarloStella C.,
Kingsley E.,
Depaus J.,
Snauwaert S.,
Kwiatek M.,
LópezJiménez J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851304.16627.3a
Subject(s) - rituximab , medicine , clinical endpoint , oncology , diffuse large b cell lymphoma , phases of clinical research , oxaliplatin , refractory (planetary science) , randomized controlled trial , lymphoma , clinical trial , cancer , colorectal cancer , physics , astrobiology